nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—MAP2K1—hematologic cancer	0.427	1	CbGaD
Trametinib—CYP2C8—Bortezomib—hematologic cancer	0.0201	0.0902	CbGbCtD
Trametinib—CYP2C8—Ifosfamide—hematologic cancer	0.0154	0.0692	CbGbCtD
Trametinib—CYP2C8—Nilotinib—hematologic cancer	0.0134	0.0601	CbGbCtD
Trametinib—CYP3A4—Bexarotene—hematologic cancer	0.0133	0.0597	CbGbCtD
Trametinib—CYP3A4—Lomustine—hematologic cancer	0.0124	0.0555	CbGbCtD
Trametinib—CYP3A4—Busulfan—hematologic cancer	0.0124	0.0555	CbGbCtD
Trametinib—CYP3A4—Thiotepa—hematologic cancer	0.011	0.0495	CbGbCtD
Trametinib—CYP3A4—Methoxsalen—hematologic cancer	0.00858	0.0385	CbGbCtD
Trametinib—CYP3A4—Bortezomib—hematologic cancer	0.00816	0.0366	CbGbCtD
Trametinib—CYP3A4—Daunorubicin—hematologic cancer	0.0078	0.035	CbGbCtD
Trametinib—CYP2C8—Etoposide—hematologic cancer	0.00737	0.0331	CbGbCtD
Trametinib—CYP3A4—Cytarabine—hematologic cancer	0.00688	0.0309	CbGbCtD
Trametinib—CYP3A4—Teniposide—hematologic cancer	0.00678	0.0304	CbGbCtD
Trametinib—CYP3A4—Ifosfamide—hematologic cancer	0.00626	0.0281	CbGbCtD
Trametinib—CYP2C8—Dexamethasone—hematologic cancer	0.00606	0.0272	CbGbCtD
Trametinib—CYP3A4—Imatinib—hematologic cancer	0.00598	0.0268	CbGbCtD
Trametinib—CYP3A4—Ruxolitinib—hematologic cancer	0.00563	0.0252	CbGbCtD
Trametinib—CYP3A4—Nilotinib—hematologic cancer	0.00543	0.0244	CbGbCtD
Trametinib—CYP3A4—Vinorelbine—hematologic cancer	0.00539	0.0242	CbGbCtD
Trametinib—CYP3A4—Triamcinolone—hematologic cancer	0.00493	0.0221	CbGbCtD
Trametinib—CYP3A4—Dasatinib—hematologic cancer	0.0048	0.0215	CbGbCtD
Trametinib—CYP3A4—Mitoxantrone—hematologic cancer	0.00474	0.0213	CbGbCtD
Trametinib—CYP3A4—Betamethasone—hematologic cancer	0.00423	0.019	CbGbCtD
Trametinib—CYP3A4—Prednisolone—hematologic cancer	0.00417	0.0187	CbGbCtD
Trametinib—CYP3A4—Prednisone—hematologic cancer	0.00394	0.0177	CbGbCtD
Trametinib—CYP3A4—Irinotecan—hematologic cancer	0.00373	0.0167	CbGbCtD
Trametinib—CYP3A4—Vinblastine—hematologic cancer	0.00332	0.0149	CbGbCtD
Trametinib—CYP3A4—Vincristine—hematologic cancer	0.00326	0.0146	CbGbCtD
Trametinib—CYP3A4—Etoposide—hematologic cancer	0.00299	0.0134	CbGbCtD
Trametinib—MAP2K1—hematopoietic system—hematologic cancer	0.00284	0.104	CbGeAlD
Trametinib—MAP2K2—hematopoietic system—hematologic cancer	0.0025	0.0912	CbGeAlD
Trametinib—CYP3A4—Dexamethasone—hematologic cancer	0.00246	0.011	CbGbCtD
Trametinib—MAP2K1—gonad—hematologic cancer	0.00216	0.0788	CbGeAlD
Trametinib—CYP3A4—Doxorubicin—hematologic cancer	0.00204	0.00915	CbGbCtD
Trametinib—MAP2K2—gonad—hematologic cancer	0.0019	0.0694	CbGeAlD
Trametinib—MAP2K1—blood—hematologic cancer	0.00188	0.0687	CbGeAlD
Trametinib—MAP2K1—bone marrow—hematologic cancer	0.00182	0.0664	CbGeAlD
Trametinib—MAP2K2—blood—hematologic cancer	0.00166	0.0604	CbGeAlD
Trametinib—MAP2K1—lung—hematologic cancer	0.00165	0.0602	CbGeAlD
Trametinib—MAP2K2—bone marrow—hematologic cancer	0.0016	0.0585	CbGeAlD
Trametinib—MAP2K1—testis—hematologic cancer	0.00156	0.0568	CbGeAlD
Trametinib—MAP2K2—lung—hematologic cancer	0.00145	0.053	CbGeAlD
Trametinib—MAP2K2—testis—hematologic cancer	0.00137	0.05	CbGeAlD
Trametinib—MAP2K1—lymph node—hematologic cancer	0.00113	0.0412	CbGeAlD
Trametinib—MAP2K2—lymph node—hematologic cancer	0.000994	0.0362	CbGeAlD
Trametinib—CYP2C8—hematopoietic system—hematologic cancer	0.000867	0.0316	CbGeAlD
Trametinib—CYP3A4—hematopoietic system—hematologic cancer	0.000587	0.0214	CbGeAlD
Trametinib—CYP2C8—blood—hematologic cancer	0.000574	0.0209	CbGeAlD
Trametinib—CYP2C8—testis—hematologic cancer	0.000475	0.0173	CbGeAlD
Trametinib—CYP3A4—blood—hematologic cancer	0.000389	0.0142	CbGeAlD
Trametinib—Urinary tract disorder—Epirubicin—hematologic cancer	1.73e-05	0.0001	CcSEcCtD
Trametinib—Rash—Vincristine—hematologic cancer	1.73e-05	0.0001	CcSEcCtD
Trametinib—Dermatitis—Vincristine—hematologic cancer	1.73e-05	0.0001	CcSEcCtD
Trametinib—Oedema peripheral—Epirubicin—hematologic cancer	1.73e-05	0.0001	CcSEcCtD
Trametinib—Haematuria—Doxorubicin—hematologic cancer	1.72e-05	9.99e-05	CcSEcCtD
Trametinib—Connective tissue disorder—Epirubicin—hematologic cancer	1.72e-05	9.99e-05	CcSEcCtD
Trametinib—Urethral disorder—Epirubicin—hematologic cancer	1.72e-05	9.97e-05	CcSEcCtD
Trametinib—Headache—Vincristine—hematologic cancer	1.72e-05	9.96e-05	CcSEcCtD
Trametinib—Nausea—Carmustine—hematologic cancer	1.71e-05	9.9e-05	CcSEcCtD
Trametinib—Epistaxis—Doxorubicin—hematologic cancer	1.7e-05	9.88e-05	CcSEcCtD
Trametinib—Angiopathy—Methotrexate—hematologic cancer	1.7e-05	9.86e-05	CcSEcCtD
Trametinib—Vomiting—Mitoxantrone—hematologic cancer	1.7e-05	9.85e-05	CcSEcCtD
Trametinib—Vomiting—Irinotecan—hematologic cancer	1.7e-05	9.85e-05	CcSEcCtD
Trametinib—Nausea—Alitretinoin—hematologic cancer	1.69e-05	9.8e-05	CcSEcCtD
Trametinib—Mediastinal disorder—Methotrexate—hematologic cancer	1.69e-05	9.79e-05	CcSEcCtD
Trametinib—Hypertension—Prednisone—hematologic cancer	1.68e-05	9.77e-05	CcSEcCtD
Trametinib—Rash—Mitoxantrone—hematologic cancer	1.68e-05	9.77e-05	CcSEcCtD
Trametinib—Rash—Irinotecan—hematologic cancer	1.68e-05	9.77e-05	CcSEcCtD
Trametinib—Dermatitis—Irinotecan—hematologic cancer	1.68e-05	9.76e-05	CcSEcCtD
Trametinib—Dermatitis—Mitoxantrone—hematologic cancer	1.68e-05	9.76e-05	CcSEcCtD
Trametinib—Chills—Methotrexate—hematologic cancer	1.68e-05	9.75e-05	CcSEcCtD
Trametinib—Headache—Irinotecan—hematologic cancer	1.67e-05	9.7e-05	CcSEcCtD
Trametinib—Headache—Mitoxantrone—hematologic cancer	1.67e-05	9.7e-05	CcSEcCtD
Trametinib—Nausea—Ifosfamide—hematologic cancer	1.67e-05	9.69e-05	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Betamethasone—hematologic cancer	1.67e-05	9.66e-05	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	1.67e-05	9.66e-05	CcSEcCtD
Trametinib—Myalgia—Prednisone—hematologic cancer	1.66e-05	9.63e-05	CcSEcCtD
Trametinib—Arthralgia—Prednisone—hematologic cancer	1.66e-05	9.63e-05	CcSEcCtD
Trametinib—Diarrhoea—Cisplatin—hematologic cancer	1.66e-05	9.62e-05	CcSEcCtD
Trametinib—Vomiting—Gemcitabine—hematologic cancer	1.65e-05	9.59e-05	CcSEcCtD
Trametinib—Insomnia—Dexamethasone—hematologic cancer	1.65e-05	9.59e-05	CcSEcCtD
Trametinib—Insomnia—Betamethasone—hematologic cancer	1.65e-05	9.59e-05	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—hematologic cancer	1.65e-05	9.58e-05	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	1.65e-05	9.57e-05	CcSEcCtD
Trametinib—Mental disorder—Methotrexate—hematologic cancer	1.64e-05	9.52e-05	CcSEcCtD
Trametinib—Rash—Gemcitabine—hematologic cancer	1.64e-05	9.51e-05	CcSEcCtD
Trametinib—Dermatitis—Gemcitabine—hematologic cancer	1.64e-05	9.51e-05	CcSEcCtD
Trametinib—Eye disorder—Epirubicin—hematologic cancer	1.64e-05	9.5e-05	CcSEcCtD
Trametinib—Malnutrition—Methotrexate—hematologic cancer	1.63e-05	9.46e-05	CcSEcCtD
Trametinib—Erythema—Methotrexate—hematologic cancer	1.63e-05	9.46e-05	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—hematologic cancer	1.63e-05	9.45e-05	CcSEcCtD
Trametinib—Headache—Gemcitabine—hematologic cancer	1.63e-05	9.45e-05	CcSEcCtD
Trametinib—Nausea—Vincristine—hematologic cancer	1.63e-05	9.45e-05	CcSEcCtD
Trametinib—Cardiac disorder—Epirubicin—hematologic cancer	1.63e-05	9.44e-05	CcSEcCtD
Trametinib—Haemorrhage—Doxorubicin—hematologic cancer	1.62e-05	9.41e-05	CcSEcCtD
Trametinib—Urinary tract disorder—Doxorubicin—hematologic cancer	1.6e-05	9.29e-05	CcSEcCtD
Trametinib—Oedema peripheral—Doxorubicin—hematologic cancer	1.6e-05	9.27e-05	CcSEcCtD
Trametinib—Dysgeusia—Methotrexate—hematologic cancer	1.6e-05	9.26e-05	CcSEcCtD
Trametinib—Asthenia—Etoposide—hematologic cancer	1.59e-05	9.24e-05	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—hematologic cancer	1.59e-05	9.24e-05	CcSEcCtD
Trametinib—Body temperature increased—Triamcinolone—hematologic cancer	1.59e-05	9.24e-05	CcSEcCtD
Trametinib—Oedema—Prednisone—hematologic cancer	1.59e-05	9.23e-05	CcSEcCtD
Trametinib—Angiopathy—Epirubicin—hematologic cancer	1.59e-05	9.22e-05	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—hematologic cancer	1.59e-05	9.22e-05	CcSEcCtD
Trametinib—Decreased appetite—Dexamethasone—hematologic cancer	1.59e-05	9.22e-05	CcSEcCtD
Trametinib—Decreased appetite—Betamethasone—hematologic cancer	1.59e-05	9.22e-05	CcSEcCtD
Trametinib—Nausea—Mitoxantrone—hematologic cancer	1.59e-05	9.2e-05	CcSEcCtD
Trametinib—Nausea—Irinotecan—hematologic cancer	1.59e-05	9.2e-05	CcSEcCtD
Trametinib—Infection—Prednisone—hematologic cancer	1.58e-05	9.17e-05	CcSEcCtD
Trametinib—Mediastinal disorder—Epirubicin—hematologic cancer	1.58e-05	9.16e-05	CcSEcCtD
Trametinib—Gastrointestinal disorder—Betamethasone—hematologic cancer	1.58e-05	9.16e-05	CcSEcCtD
Trametinib—Gastrointestinal disorder—Dexamethasone—hematologic cancer	1.58e-05	9.16e-05	CcSEcCtD
Trametinib—Back pain—Methotrexate—hematologic cancer	1.58e-05	9.15e-05	CcSEcCtD
Trametinib—Fatigue—Dexamethasone—hematologic cancer	1.58e-05	9.14e-05	CcSEcCtD
Trametinib—Fatigue—Betamethasone—hematologic cancer	1.58e-05	9.14e-05	CcSEcCtD
Trametinib—Chills—Epirubicin—hematologic cancer	1.57e-05	9.12e-05	CcSEcCtD
Trametinib—Pruritus—Etoposide—hematologic cancer	1.57e-05	9.12e-05	CcSEcCtD
Trametinib—Arrhythmia—Epirubicin—hematologic cancer	1.57e-05	9.08e-05	CcSEcCtD
Trametinib—Nervous system disorder—Prednisone—hematologic cancer	1.56e-05	9.06e-05	CcSEcCtD
Trametinib—Skin disorder—Prednisone—hematologic cancer	1.55e-05	8.97e-05	CcSEcCtD
Trametinib—Nausea—Gemcitabine—hematologic cancer	1.54e-05	8.96e-05	CcSEcCtD
Trametinib—Vomiting—Cisplatin—hematologic cancer	1.54e-05	8.94e-05	CcSEcCtD
Trametinib—Hyperhidrosis—Prednisone—hematologic cancer	1.54e-05	8.93e-05	CcSEcCtD
Trametinib—Vision blurred—Methotrexate—hematologic cancer	1.54e-05	8.91e-05	CcSEcCtD
Trametinib—Mental disorder—Epirubicin—hematologic cancer	1.54e-05	8.91e-05	CcSEcCtD
Trametinib—Rash—Cisplatin—hematologic cancer	1.53e-05	8.87e-05	CcSEcCtD
Trametinib—Dermatitis—Cisplatin—hematologic cancer	1.53e-05	8.86e-05	CcSEcCtD
Trametinib—Malnutrition—Epirubicin—hematologic cancer	1.53e-05	8.85e-05	CcSEcCtD
Trametinib—Erythema—Epirubicin—hematologic cancer	1.53e-05	8.85e-05	CcSEcCtD
Trametinib—Diarrhoea—Etoposide—hematologic cancer	1.52e-05	8.82e-05	CcSEcCtD
Trametinib—Eye disorder—Doxorubicin—hematologic cancer	1.52e-05	8.79e-05	CcSEcCtD
Trametinib—Anaemia—Methotrexate—hematologic cancer	1.51e-05	8.74e-05	CcSEcCtD
Trametinib—Cardiac disorder—Doxorubicin—hematologic cancer	1.5e-05	8.73e-05	CcSEcCtD
Trametinib—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.49e-05	8.67e-05	CcSEcCtD
Trametinib—Gastrointestinal pain—Betamethasone—hematologic cancer	1.49e-05	8.67e-05	CcSEcCtD
Trametinib—Dysgeusia—Epirubicin—hematologic cancer	1.49e-05	8.67e-05	CcSEcCtD
Trametinib—Back pain—Epirubicin—hematologic cancer	1.48e-05	8.56e-05	CcSEcCtD
Trametinib—Angiopathy—Doxorubicin—hematologic cancer	1.47e-05	8.53e-05	CcSEcCtD
Trametinib—Dizziness—Etoposide—hematologic cancer	1.47e-05	8.52e-05	CcSEcCtD
Trametinib—Muscle spasms—Epirubicin—hematologic cancer	1.47e-05	8.51e-05	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—hematologic cancer	1.46e-05	8.48e-05	CcSEcCtD
Trametinib—Leukopenia—Methotrexate—hematologic cancer	1.46e-05	8.46e-05	CcSEcCtD
Trametinib—Chills—Doxorubicin—hematologic cancer	1.45e-05	8.44e-05	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.45e-05	8.41e-05	CcSEcCtD
Trametinib—Dizziness—Prednisolone—hematologic cancer	1.45e-05	8.4e-05	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—hematologic cancer	1.45e-05	8.4e-05	CcSEcCtD
Trametinib—Asthenia—Triamcinolone—hematologic cancer	1.45e-05	8.39e-05	CcSEcCtD
Trametinib—Body temperature increased—Betamethasone—hematologic cancer	1.44e-05	8.38e-05	CcSEcCtD
Trametinib—Body temperature increased—Dexamethasone—hematologic cancer	1.44e-05	8.38e-05	CcSEcCtD
Trametinib—Abdominal pain—Betamethasone—hematologic cancer	1.44e-05	8.38e-05	CcSEcCtD
Trametinib—Abdominal pain—Dexamethasone—hematologic cancer	1.44e-05	8.38e-05	CcSEcCtD
Trametinib—Nausea—Cisplatin—hematologic cancer	1.44e-05	8.35e-05	CcSEcCtD
Trametinib—Insomnia—Prednisone—hematologic cancer	1.44e-05	8.35e-05	CcSEcCtD
Trametinib—Vision blurred—Epirubicin—hematologic cancer	1.44e-05	8.34e-05	CcSEcCtD
Trametinib—Pruritus—Triamcinolone—hematologic cancer	1.43e-05	8.27e-05	CcSEcCtD
Trametinib—Cough—Methotrexate—hematologic cancer	1.42e-05	8.25e-05	CcSEcCtD
Trametinib—Mental disorder—Doxorubicin—hematologic cancer	1.42e-05	8.24e-05	CcSEcCtD
Trametinib—Vomiting—Etoposide—hematologic cancer	1.41e-05	8.19e-05	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—hematologic cancer	1.41e-05	8.19e-05	CcSEcCtD
Trametinib—Erythema—Doxorubicin—hematologic cancer	1.41e-05	8.19e-05	CcSEcCtD
Trametinib—Anaemia—Epirubicin—hematologic cancer	1.41e-05	8.18e-05	CcSEcCtD
Trametinib—Rash—Etoposide—hematologic cancer	1.4e-05	8.12e-05	CcSEcCtD
Trametinib—Dermatitis—Etoposide—hematologic cancer	1.4e-05	8.12e-05	CcSEcCtD
Trametinib—Headache—Etoposide—hematologic cancer	1.39e-05	8.07e-05	CcSEcCtD
Trametinib—Arthralgia—Methotrexate—hematologic cancer	1.39e-05	8.05e-05	CcSEcCtD
Trametinib—Myalgia—Methotrexate—hematologic cancer	1.39e-05	8.05e-05	CcSEcCtD
Trametinib—Decreased appetite—Prednisone—hematologic cancer	1.38e-05	8.03e-05	CcSEcCtD
Trametinib—Dysgeusia—Doxorubicin—hematologic cancer	1.38e-05	8.02e-05	CcSEcCtD
Trametinib—Rash—Prednisolone—hematologic cancer	1.38e-05	8.01e-05	CcSEcCtD
Trametinib—Dermatitis—Prednisolone—hematologic cancer	1.38e-05	8.01e-05	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.38e-05	8e-05	CcSEcCtD
Trametinib—Fatigue—Prednisone—hematologic cancer	1.37e-05	7.96e-05	CcSEcCtD
Trametinib—Headache—Prednisolone—hematologic cancer	1.37e-05	7.96e-05	CcSEcCtD
Trametinib—Leukopenia—Epirubicin—hematologic cancer	1.37e-05	7.92e-05	CcSEcCtD
Trametinib—Back pain—Doxorubicin—hematologic cancer	1.37e-05	7.92e-05	CcSEcCtD
Trametinib—Constipation—Prednisone—hematologic cancer	1.36e-05	7.9e-05	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—hematologic cancer	1.36e-05	7.87e-05	CcSEcCtD
Trametinib—Dizziness—Triamcinolone—hematologic cancer	1.33e-05	7.73e-05	CcSEcCtD
Trametinib—Cough—Epirubicin—hematologic cancer	1.33e-05	7.72e-05	CcSEcCtD
Trametinib—Vision blurred—Doxorubicin—hematologic cancer	1.33e-05	7.72e-05	CcSEcCtD
Trametinib—Infection—Methotrexate—hematologic cancer	1.32e-05	7.67e-05	CcSEcCtD
Trametinib—Nausea—Etoposide—hematologic cancer	1.32e-05	7.65e-05	CcSEcCtD
Trametinib—Hypertension—Epirubicin—hematologic cancer	1.32e-05	7.64e-05	CcSEcCtD
Trametinib—Asthenia—Betamethasone—hematologic cancer	1.31e-05	7.61e-05	CcSEcCtD
Trametinib—Asthenia—Dexamethasone—hematologic cancer	1.31e-05	7.61e-05	CcSEcCtD
Trametinib—Nervous system disorder—Methotrexate—hematologic cancer	1.3e-05	7.57e-05	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—hematologic cancer	1.3e-05	7.57e-05	CcSEcCtD
Trametinib—Thrombocytopenia—Methotrexate—hematologic cancer	1.3e-05	7.56e-05	CcSEcCtD
Trametinib—Gastrointestinal pain—Prednisone—hematologic cancer	1.3e-05	7.55e-05	CcSEcCtD
Trametinib—Nausea—Prednisolone—hematologic cancer	1.3e-05	7.55e-05	CcSEcCtD
Trametinib—Myalgia—Epirubicin—hematologic cancer	1.3e-05	7.53e-05	CcSEcCtD
Trametinib—Arthralgia—Epirubicin—hematologic cancer	1.3e-05	7.53e-05	CcSEcCtD
Trametinib—Pruritus—Betamethasone—hematologic cancer	1.29e-05	7.5e-05	CcSEcCtD
Trametinib—Pruritus—Dexamethasone—hematologic cancer	1.29e-05	7.5e-05	CcSEcCtD
Trametinib—Skin disorder—Methotrexate—hematologic cancer	1.29e-05	7.5e-05	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.29e-05	7.48e-05	CcSEcCtD
Trametinib—Hyperhidrosis—Methotrexate—hematologic cancer	1.29e-05	7.46e-05	CcSEcCtD
Trametinib—Vomiting—Triamcinolone—hematologic cancer	1.28e-05	7.43e-05	CcSEcCtD
Trametinib—Rash—Triamcinolone—hematologic cancer	1.27e-05	7.37e-05	CcSEcCtD
Trametinib—Dry mouth—Epirubicin—hematologic cancer	1.27e-05	7.37e-05	CcSEcCtD
Trametinib—Dermatitis—Triamcinolone—hematologic cancer	1.27e-05	7.36e-05	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—hematologic cancer	1.26e-05	7.33e-05	CcSEcCtD
Trametinib—Headache—Triamcinolone—hematologic cancer	1.26e-05	7.32e-05	CcSEcCtD
Trametinib—Body temperature increased—Prednisone—hematologic cancer	1.26e-05	7.3e-05	CcSEcCtD
Trametinib—Abdominal pain—Prednisone—hematologic cancer	1.26e-05	7.3e-05	CcSEcCtD
Trametinib—Diarrhoea—Dexamethasone—hematologic cancer	1.25e-05	7.26e-05	CcSEcCtD
Trametinib—Diarrhoea—Betamethasone—hematologic cancer	1.25e-05	7.26e-05	CcSEcCtD
Trametinib—Oedema—Epirubicin—hematologic cancer	1.24e-05	7.22e-05	CcSEcCtD
Trametinib—Infection—Epirubicin—hematologic cancer	1.24e-05	7.18e-05	CcSEcCtD
Trametinib—Cough—Doxorubicin—hematologic cancer	1.23e-05	7.15e-05	CcSEcCtD
Trametinib—Nervous system disorder—Epirubicin—hematologic cancer	1.22e-05	7.08e-05	CcSEcCtD
Trametinib—Thrombocytopenia—Epirubicin—hematologic cancer	1.22e-05	7.07e-05	CcSEcCtD
Trametinib—Hypertension—Doxorubicin—hematologic cancer	1.22e-05	7.07e-05	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.21e-05	7.03e-05	CcSEcCtD
Trametinib—Skin disorder—Epirubicin—hematologic cancer	1.21e-05	7.02e-05	CcSEcCtD
Trametinib—Dizziness—Betamethasone—hematologic cancer	1.21e-05	7.01e-05	CcSEcCtD
Trametinib—Dizziness—Dexamethasone—hematologic cancer	1.21e-05	7.01e-05	CcSEcCtD
Trametinib—Hyperhidrosis—Epirubicin—hematologic cancer	1.2e-05	6.98e-05	CcSEcCtD
Trametinib—Insomnia—Methotrexate—hematologic cancer	1.2e-05	6.98e-05	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—hematologic cancer	1.2e-05	6.97e-05	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—hematologic cancer	1.2e-05	6.97e-05	CcSEcCtD
Trametinib—Nausea—Triamcinolone—hematologic cancer	1.2e-05	6.94e-05	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.19e-05	6.92e-05	CcSEcCtD
Trametinib—Dry mouth—Doxorubicin—hematologic cancer	1.18e-05	6.82e-05	CcSEcCtD
Trametinib—Vomiting—Betamethasone—hematologic cancer	1.16e-05	6.74e-05	CcSEcCtD
Trametinib—Vomiting—Dexamethasone—hematologic cancer	1.16e-05	6.74e-05	CcSEcCtD
Trametinib—Decreased appetite—Methotrexate—hematologic cancer	1.16e-05	6.71e-05	CcSEcCtD
Trametinib—Rash—Dexamethasone—hematologic cancer	1.15e-05	6.69e-05	CcSEcCtD
Trametinib—Rash—Betamethasone—hematologic cancer	1.15e-05	6.69e-05	CcSEcCtD
Trametinib—Oedema—Doxorubicin—hematologic cancer	1.15e-05	6.68e-05	CcSEcCtD
Trametinib—Dermatitis—Betamethasone—hematologic cancer	1.15e-05	6.68e-05	CcSEcCtD
Trametinib—Dermatitis—Dexamethasone—hematologic cancer	1.15e-05	6.68e-05	CcSEcCtD
Trametinib—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.15e-05	6.66e-05	CcSEcCtD
Trametinib—Fatigue—Methotrexate—hematologic cancer	1.15e-05	6.65e-05	CcSEcCtD
Trametinib—Headache—Betamethasone—hematologic cancer	1.15e-05	6.64e-05	CcSEcCtD
Trametinib—Headache—Dexamethasone—hematologic cancer	1.15e-05	6.64e-05	CcSEcCtD
Trametinib—Infection—Doxorubicin—hematologic cancer	1.14e-05	6.64e-05	CcSEcCtD
Trametinib—Asthenia—Prednisone—hematologic cancer	1.14e-05	6.63e-05	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.13e-05	6.58e-05	CcSEcCtD
Trametinib—Nervous system disorder—Doxorubicin—hematologic cancer	1.13e-05	6.55e-05	CcSEcCtD
Trametinib—Thrombocytopenia—Doxorubicin—hematologic cancer	1.13e-05	6.54e-05	CcSEcCtD
Trametinib—Pruritus—Prednisone—hematologic cancer	1.13e-05	6.53e-05	CcSEcCtD
Trametinib—Insomnia—Epirubicin—hematologic cancer	1.13e-05	6.53e-05	CcSEcCtD
Trametinib—Skin disorder—Doxorubicin—hematologic cancer	1.12e-05	6.49e-05	CcSEcCtD
Trametinib—Hyperhidrosis—Doxorubicin—hematologic cancer	1.11e-05	6.46e-05	CcSEcCtD
Trametinib—Diarrhoea—Prednisone—hematologic cancer	1.09e-05	6.32e-05	CcSEcCtD
Trametinib—Gastrointestinal pain—Methotrexate—hematologic cancer	1.09e-05	6.31e-05	CcSEcCtD
Trametinib—Nausea—Dexamethasone—hematologic cancer	1.09e-05	6.3e-05	CcSEcCtD
Trametinib—Nausea—Betamethasone—hematologic cancer	1.09e-05	6.3e-05	CcSEcCtD
Trametinib—Decreased appetite—Epirubicin—hematologic cancer	1.08e-05	6.28e-05	CcSEcCtD
Trametinib—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.07e-05	6.24e-05	CcSEcCtD
Trametinib—Fatigue—Epirubicin—hematologic cancer	1.07e-05	6.23e-05	CcSEcCtD
Trametinib—Constipation—Epirubicin—hematologic cancer	1.06e-05	6.18e-05	CcSEcCtD
Trametinib—Dizziness—Prednisone—hematologic cancer	1.05e-05	6.11e-05	CcSEcCtD
Trametinib—Body temperature increased—Methotrexate—hematologic cancer	1.05e-05	6.1e-05	CcSEcCtD
Trametinib—Abdominal pain—Methotrexate—hematologic cancer	1.05e-05	6.1e-05	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.05e-05	6.09e-05	CcSEcCtD
Trametinib—Insomnia—Doxorubicin—hematologic cancer	1.04e-05	6.04e-05	CcSEcCtD
Trametinib—Gastrointestinal pain—Epirubicin—hematologic cancer	1.02e-05	5.91e-05	CcSEcCtD
Trametinib—Vomiting—Prednisone—hematologic cancer	1.01e-05	5.87e-05	CcSEcCtD
Trametinib—Rash—Prednisone—hematologic cancer	1e-05	5.82e-05	CcSEcCtD
Trametinib—Dermatitis—Prednisone—hematologic cancer	1e-05	5.82e-05	CcSEcCtD
Trametinib—Decreased appetite—Doxorubicin—hematologic cancer	1e-05	5.81e-05	CcSEcCtD
Trametinib—Headache—Prednisone—hematologic cancer	9.97e-06	5.79e-05	CcSEcCtD
Trametinib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	9.95e-06	5.77e-05	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—hematologic cancer	9.93e-06	5.76e-05	CcSEcCtD
Trametinib—Constipation—Doxorubicin—hematologic cancer	9.85e-06	5.71e-05	CcSEcCtD
Trametinib—Body temperature increased—Epirubicin—hematologic cancer	9.84e-06	5.71e-05	CcSEcCtD
Trametinib—Abdominal pain—Epirubicin—hematologic cancer	9.84e-06	5.71e-05	CcSEcCtD
Trametinib—Asthenia—Methotrexate—hematologic cancer	9.54e-06	5.54e-05	CcSEcCtD
Trametinib—Nausea—Prednisone—hematologic cancer	9.46e-06	5.49e-05	CcSEcCtD
Trametinib—Gastrointestinal pain—Doxorubicin—hematologic cancer	9.42e-06	5.46e-05	CcSEcCtD
Trametinib—Pruritus—Methotrexate—hematologic cancer	9.41e-06	5.46e-05	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—hematologic cancer	9.11e-06	5.28e-05	CcSEcCtD
Trametinib—Abdominal pain—Doxorubicin—hematologic cancer	9.11e-06	5.28e-05	CcSEcCtD
Trametinib—Diarrhoea—Methotrexate—hematologic cancer	9.1e-06	5.28e-05	CcSEcCtD
Trametinib—Asthenia—Epirubicin—hematologic cancer	8.93e-06	5.18e-05	CcSEcCtD
Trametinib—Pruritus—Epirubicin—hematologic cancer	8.81e-06	5.11e-05	CcSEcCtD
Trametinib—Dizziness—Methotrexate—hematologic cancer	8.8e-06	5.1e-05	CcSEcCtD
Trametinib—Diarrhoea—Epirubicin—hematologic cancer	8.52e-06	4.94e-05	CcSEcCtD
Trametinib—Vomiting—Methotrexate—hematologic cancer	8.46e-06	4.91e-05	CcSEcCtD
Trametinib—Rash—Methotrexate—hematologic cancer	8.39e-06	4.87e-05	CcSEcCtD
Trametinib—Dermatitis—Methotrexate—hematologic cancer	8.38e-06	4.86e-05	CcSEcCtD
Trametinib—Headache—Methotrexate—hematologic cancer	8.33e-06	4.84e-05	CcSEcCtD
Trametinib—Asthenia—Doxorubicin—hematologic cancer	8.26e-06	4.79e-05	CcSEcCtD
Trametinib—Dizziness—Epirubicin—hematologic cancer	8.23e-06	4.78e-05	CcSEcCtD
Trametinib—Pruritus—Doxorubicin—hematologic cancer	8.15e-06	4.73e-05	CcSEcCtD
Trametinib—Vomiting—Epirubicin—hematologic cancer	7.92e-06	4.59e-05	CcSEcCtD
Trametinib—Nausea—Methotrexate—hematologic cancer	7.9e-06	4.58e-05	CcSEcCtD
Trametinib—Diarrhoea—Doxorubicin—hematologic cancer	7.88e-06	4.57e-05	CcSEcCtD
Trametinib—Rash—Epirubicin—hematologic cancer	7.85e-06	4.55e-05	CcSEcCtD
Trametinib—Dermatitis—Epirubicin—hematologic cancer	7.84e-06	4.55e-05	CcSEcCtD
Trametinib—Headache—Epirubicin—hematologic cancer	7.8e-06	4.52e-05	CcSEcCtD
Trametinib—Dizziness—Doxorubicin—hematologic cancer	7.62e-06	4.42e-05	CcSEcCtD
Trametinib—Nausea—Epirubicin—hematologic cancer	7.39e-06	4.29e-05	CcSEcCtD
Trametinib—Vomiting—Doxorubicin—hematologic cancer	7.32e-06	4.25e-05	CcSEcCtD
Trametinib—Rash—Doxorubicin—hematologic cancer	7.26e-06	4.21e-05	CcSEcCtD
Trametinib—Dermatitis—Doxorubicin—hematologic cancer	7.26e-06	4.21e-05	CcSEcCtD
Trametinib—Headache—Doxorubicin—hematologic cancer	7.22e-06	4.19e-05	CcSEcCtD
Trametinib—Nausea—Doxorubicin—hematologic cancer	6.84e-06	3.97e-05	CcSEcCtD
Trametinib—MAP2K2—Immune System—IL1B—hematologic cancer	2.01e-06	1.33e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CD4—hematologic cancer	2.01e-06	1.33e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FGFR3—hematologic cancer	2e-06	1.33e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL2—hematologic cancer	2e-06	1.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PDGFB—hematologic cancer	1.99e-06	1.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK14—hematologic cancer	1.98e-06	1.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—JAK2—hematologic cancer	1.98e-06	1.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HRAS—hematologic cancer	1.97e-06	1.31e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—AKT1—hematologic cancer	1.97e-06	1.31e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TSC2—hematologic cancer	1.94e-06	1.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—JUN—hematologic cancer	1.94e-06	1.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ESR1—hematologic cancer	1.94e-06	1.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MDM2—hematologic cancer	1.93e-06	1.29e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.93e-06	1.28e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FN1—hematologic cancer	1.92e-06	1.28e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—FHL2—hematologic cancer	1.91e-06	1.27e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDKN1B—hematologic cancer	1.91e-06	1.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NFKBIA—hematologic cancer	1.9e-06	1.26e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—BAD—hematologic cancer	1.9e-06	1.26e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6—hematologic cancer	1.89e-06	1.26e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1B—hematologic cancer	1.89e-06	1.25e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDKN1A—hematologic cancer	1.88e-06	1.25e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PTEN—hematologic cancer	1.88e-06	1.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MTOR—hematologic cancer	1.88e-06	1.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CB—hematologic cancer	1.88e-06	1.25e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOTCH1—hematologic cancer	1.88e-06	1.25e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AGRN—hematologic cancer	1.88e-06	1.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL1B—hematologic cancer	1.88e-06	1.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CD4—hematologic cancer	1.88e-06	1.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FGFR3—hematologic cancer	1.87e-06	1.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL2—hematologic cancer	1.87e-06	1.24e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT1—hematologic cancer	1.86e-06	1.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK14—hematologic cancer	1.85e-06	1.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK8—hematologic cancer	1.84e-06	1.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CD80—hematologic cancer	1.84e-06	1.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CG—hematologic cancer	1.84e-06	1.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KIT—hematologic cancer	1.84e-06	1.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—NRAS—hematologic cancer	1.84e-06	1.22e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—JUN—hematologic cancer	1.82e-06	1.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ESR1—hematologic cancer	1.82e-06	1.21e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NQO1—hematologic cancer	1.82e-06	1.21e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CD44—hematologic cancer	1.82e-06	1.21e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTPN11—hematologic cancer	1.8e-06	1.2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FN1—hematologic cancer	1.79e-06	1.19e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EP300—hematologic cancer	1.79e-06	1.19e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—IDH2—hematologic cancer	1.78e-06	1.18e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HMMR—hematologic cancer	1.78e-06	1.18e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.78e-06	1.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—BAD—hematologic cancer	1.77e-06	1.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NFKBIA—hematologic cancer	1.77e-06	1.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1B—hematologic cancer	1.76e-06	1.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDKN1A—hematologic cancer	1.76e-06	1.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTEN—hematologic cancer	1.76e-06	1.17e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—MAPK3—hematologic cancer	1.76e-06	1.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOTCH1—hematologic cancer	1.76e-06	1.17e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CREB1—hematologic cancer	1.75e-06	1.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—SRC—hematologic cancer	1.74e-06	1.16e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—hematologic cancer	1.74e-06	1.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1A—hematologic cancer	1.74e-06	1.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTEN—hematologic cancer	1.74e-06	1.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—BRAF—hematologic cancer	1.73e-06	1.15e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK8—hematologic cancer	1.72e-06	1.15e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CD80—hematologic cancer	1.72e-06	1.15e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYCS—hematologic cancer	1.72e-06	1.14e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CG—hematologic cancer	1.72e-06	1.14e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KIT—hematologic cancer	1.72e-06	1.14e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—NRAS—hematologic cancer	1.72e-06	1.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCL2—hematologic cancer	1.71e-06	1.14e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HSP90AA1—hematologic cancer	1.71e-06	1.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6R—hematologic cancer	1.7e-06	1.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CREBBP—hematologic cancer	1.7e-06	1.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTPN11—hematologic cancer	1.69e-06	1.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STAT3—hematologic cancer	1.68e-06	1.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EP300—hematologic cancer	1.68e-06	1.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NRAS—hematologic cancer	1.68e-06	1.12e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ARNTL—hematologic cancer	1.67e-06	1.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EP300—hematologic cancer	1.66e-06	1.1e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—MAPK3—hematologic cancer	1.65e-06	1.09e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CREB1—hematologic cancer	1.64e-06	1.09e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—SRC—hematologic cancer	1.63e-06	1.09e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1A—hematologic cancer	1.63e-06	1.08e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CA9—hematologic cancer	1.63e-06	1.08e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ACP5—hematologic cancer	1.63e-06	1.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAP2K1—hematologic cancer	1.62e-06	1.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTEN—hematologic cancer	1.62e-06	1.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—BRAF—hematologic cancer	1.61e-06	1.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CD—hematologic cancer	1.61e-06	1.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SRC—hematologic cancer	1.61e-06	1.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK3—hematologic cancer	1.61e-06	1.07e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NCOR2—hematologic cancer	1.61e-06	1.07e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCL2—hematologic cancer	1.6e-06	1.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6R—hematologic cancer	1.59e-06	1.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CREBBP—hematologic cancer	1.59e-06	1.06e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—hematologic cancer	1.58e-06	1.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STAT3—hematologic cancer	1.57e-06	1.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NRAS—hematologic cancer	1.57e-06	1.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STAT3—hematologic cancer	1.55e-06	1.03e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EP300—hematologic cancer	1.55e-06	1.03e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NRAS—hematologic cancer	1.55e-06	1.03e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FGF2—hematologic cancer	1.55e-06	1.03e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.54e-06	1.02e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—IDH1—hematologic cancer	1.53e-06	1.02e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3R1—hematologic cancer	1.52e-06	1.01e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTP1—hematologic cancer	1.51e-06	1.01e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.51e-06	1.01e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TXN—hematologic cancer	1.51e-06	1.01e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.51e-06	1.01e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CD—hematologic cancer	1.51e-06	1e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SRC—hematologic cancer	1.51e-06	1e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK3—hematologic cancer	1.5e-06	1e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MAPK3—hematologic cancer	1.48e-06	9.87e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—JAK2—hematologic cancer	1.48e-06	9.86e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.48e-06	9.85e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—hematologic cancer	1.48e-06	9.84e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.47e-06	9.76e-06	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STAT3—hematologic cancer	1.45e-06	9.67e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CA—hematologic cancer	1.45e-06	9.66e-06	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NRAS—hematologic cancer	1.45e-06	9.64e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MDM2—hematologic cancer	1.45e-06	9.62e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FGF2—hematologic cancer	1.45e-06	9.62e-06	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—hematologic cancer	1.44e-06	9.61e-06	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—hematologic cancer	1.44e-06	9.6e-06	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFB1—hematologic cancer	1.44e-06	9.58e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ABCB1—hematologic cancer	1.43e-06	9.54e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3R1—hematologic cancer	1.43e-06	9.49e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—UGT1A1—hematologic cancer	1.42e-06	9.47e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CB—hematologic cancer	1.41e-06	9.36e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MTOR—hematologic cancer	1.41e-06	9.36e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NCOR1—hematologic cancer	1.39e-06	9.27e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTM1—hematologic cancer	1.39e-06	9.27e-06	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MAPK3—hematologic cancer	1.39e-06	9.24e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—JAK2—hematologic cancer	1.39e-06	9.22e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CRABP1—hematologic cancer	1.38e-06	9.21e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC22A1—hematologic cancer	1.38e-06	9.21e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CA—hematologic cancer	1.36e-06	9.04e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MDM2—hematologic cancer	1.35e-06	9e-06	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—hematologic cancer	1.35e-06	8.99e-06	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—hematologic cancer	1.35e-06	8.98e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALOX5—hematologic cancer	1.35e-06	8.98e-06	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFB1—hematologic cancer	1.35e-06	8.96e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRAS—hematologic cancer	1.34e-06	8.94e-06	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—hematologic cancer	1.33e-06	8.87e-06	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CA—hematologic cancer	1.33e-06	8.83e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1B—hematologic cancer	1.32e-06	8.79e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CB—hematologic cancer	1.32e-06	8.76e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MTOR—hematologic cancer	1.32e-06	8.76e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NUP98—hematologic cancer	1.31e-06	8.69e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CASP3—hematologic cancer	1.29e-06	8.61e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL2—hematologic cancer	1.29e-06	8.6e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—hematologic cancer	1.29e-06	8.56e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ADCY7—hematologic cancer	1.27e-06	8.44e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NCOA3—hematologic cancer	1.27e-06	8.44e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—hematologic cancer	1.26e-06	8.38e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NUP214—hematologic cancer	1.26e-06	8.38e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—JUN—hematologic cancer	1.26e-06	8.36e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRAS—hematologic cancer	1.26e-06	8.36e-06	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—hematologic cancer	1.25e-06	8.3e-06	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CA—hematologic cancer	1.24e-06	8.26e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1B—hematologic cancer	1.24e-06	8.22e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCG2—hematologic cancer	1.23e-06	8.21e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MTR—hematologic cancer	1.23e-06	8.21e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—MTHFR—hematologic cancer	1.23e-06	8.19e-06	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HRAS—hematologic cancer	1.23e-06	8.17e-06	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CA—hematologic cancer	1.22e-06	8.15e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1A—hematologic cancer	1.22e-06	8.11e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTEN—hematologic cancer	1.22e-06	8.09e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CASP3—hematologic cancer	1.21e-06	8.06e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ENO2—hematologic cancer	1.21e-06	8.05e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL2—hematologic cancer	1.21e-06	8.04e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—hematologic cancer	1.2e-06	8e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK8—hematologic cancer	1.19e-06	7.91e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—hematologic cancer	1.19e-06	7.89e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—hematologic cancer	1.18e-06	7.84e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—JUN—hematologic cancer	1.18e-06	7.83e-06	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—hematologic cancer	1.17e-06	7.82e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.17e-06	7.81e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EP300—hematologic cancer	1.16e-06	7.72e-06	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HRAS—hematologic cancer	1.15e-06	7.64e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SDC1—hematologic cancer	1.15e-06	7.63e-06	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CA—hematologic cancer	1.15e-06	7.63e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1A—hematologic cancer	1.14e-06	7.59e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTEN—hematologic cancer	1.14e-06	7.57e-06	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HRAS—hematologic cancer	1.13e-06	7.54e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SRC—hematologic cancer	1.13e-06	7.5e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK8—hematologic cancer	1.11e-06	7.4e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—hematologic cancer	1.11e-06	7.38e-06	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—hematologic cancer	1.1e-06	7.31e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—hematologic cancer	1.1e-06	7.31e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT3—hematologic cancer	1.09e-06	7.24e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EP300—hematologic cancer	1.08e-06	7.22e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NRAS—hematologic cancer	1.08e-06	7.22e-06	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—hematologic cancer	1.08e-06	7.22e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.08e-06	7.22e-06	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—hematologic cancer	1.08e-06	7.21e-06	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HRAS—hematologic cancer	1.06e-06	7.06e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SRC—hematologic cancer	1.05e-06	7.02e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK3—hematologic cancer	1.04e-06	6.91e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CG—hematologic cancer	1.03e-06	6.88e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—hematologic cancer	1.03e-06	6.84e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STAT3—hematologic cancer	1.02e-06	6.77e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NRAS—hematologic cancer	1.01e-06	6.75e-06	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—hematologic cancer	1.01e-06	6.75e-06	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—hematologic cancer	1.01e-06	6.75e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—hematologic cancer	1.01e-06	6.72e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFB1—hematologic cancer	1.01e-06	6.71e-06	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—hematologic cancer	1e-06	6.66e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CD44—hematologic cancer	9.75e-07	6.49e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NQO1—hematologic cancer	9.75e-07	6.49e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK3—hematologic cancer	9.72e-07	6.47e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CREBBP—hematologic cancer	9.58e-07	6.38e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—hematologic cancer	9.45e-07	6.29e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFB1—hematologic cancer	9.43e-07	6.28e-06	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—hematologic cancer	9.36e-07	6.23e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—hematologic cancer	9.33e-07	6.21e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYCS—hematologic cancer	9.23e-07	6.14e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	9.17e-07	6.1e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CD—hematologic cancer	9.09e-07	6.05e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALB—hematologic cancer	8.97e-07	5.97e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—hematologic cancer	8.73e-07	5.81e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3R1—hematologic cancer	8.58e-07	5.71e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CA—hematologic cancer	8.58e-07	5.71e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—hematologic cancer	8.3e-07	5.52e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTP1—hematologic cancer	8.13e-07	5.41e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CA—hematologic cancer	8.02e-07	5.34e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRAS—hematologic cancer	7.93e-07	5.28e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CB—hematologic cancer	7.92e-07	5.27e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—hematologic cancer	7.76e-07	5.17e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCB1—hematologic cancer	7.7e-07	5.12e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—hematologic cancer	7.59e-07	5.05e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTM1—hematologic cancer	7.47e-07	4.97e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NCOR1—hematologic cancer	7.47e-07	4.97e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRAS—hematologic cancer	7.42e-07	4.94e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—hematologic cancer	7.1e-07	4.73e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT1—hematologic cancer	7.01e-07	4.66e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTEN—hematologic cancer	6.84e-07	4.56e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MTHFR—hematologic cancer	6.6e-07	4.4e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—hematologic cancer	6.55e-07	4.36e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—EP300—hematologic cancer	6.53e-07	4.34e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	5.55e-07	3.69e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CREBBP—hematologic cancer	5.14e-07	3.42e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	4.88e-07	3.25e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CA—hematologic cancer	4.83e-07	3.21e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALB—hematologic cancer	4.82e-07	3.2e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	4.61e-07	3.07e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	4.25e-07	2.83e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—hematologic cancer	3.94e-07	2.63e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTEN—hematologic cancer	3.67e-07	2.45e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—EP300—hematologic cancer	3.5e-07	2.33e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	2.59e-07	1.72e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—hematologic cancer	2.12e-07	1.41e-06	CbGpPWpGaD
